Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of ALKS 2680 in Narcolepsy and Idiopathic Hypersomnia
NCT06767683Phase 3Recruiting
- Sponsor
- Alkermes
- Start
- Jan 2025
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of alixorexton in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), sponsored by Alkermes. Started Jan 2025; status: recruiting.
02
Drugs
alixorexton
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)idiopathic hypersomnia (IH)
Beyond the preview
Go deeper on NCT06767683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06767683.